Sonnet BioTherapeutics Holdings, Inc. (SONN): Price and Financial Metrics


Sonnet BioTherapeutics Holdings, Inc. (SONN): $0.27

0.00 (1.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SONN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SONN POWR Grades


  • SONN scores best on the Sentiment dimension, with a Sentiment rank ahead of 98.96% of US stocks.
  • SONN's strongest trending metric is Sentiment; it's been moving up over the last 169 days.
  • SONN's current lowest rank is in the Stability metric (where it is better than 2.03% of US stocks).

SONN Stock Summary

  • Revenue growth over the past 12 months for Sonnet BioTherapeutics Holdings Inc comes in at -89.2%, a number that bests only 1.11% of the US stocks we're tracking.
  • The volatility of Sonnet BioTherapeutics Holdings Inc's share price is greater than that of 97.24% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SONN comes in at -185.2% -- higher than that of only 1.68% of stocks in our set.
  • Stocks that are quantitatively similar to SONN, based on their financial statements, market capitalization, and price volatility, are INFI, ZSAN, IPHA, BBI, and DRRX.
  • SONN's SEC filings can be seen here. And to visit Sonnet BioTherapeutics Holdings Inc's official web site, go to www.sonnetbio.com.

SONN Valuation Summary

  • In comparison to the median Healthcare stock, SONN's EV/EBIT ratio is 101.37% lower, now standing at -0.4.
  • Over the past 181 months, SONN's price/sales ratio has gone NA NA.
  • Over the past 181 months, SONN's price/earnings ratio has gone up 68.8.

Below are key valuation metrics over time for SONN.

Stock Date P/S P/B P/E EV/EBIT
SONN 2021-08-31 NA 12.6 -0.3 -0.4
SONN 2021-08-30 NA 10.2 -0.2 -0.3
SONN 2021-08-27 NA 10.5 -0.2 -0.3
SONN 2021-08-26 NA 10.4 -0.2 -0.3
SONN 2021-08-25 NA 11.0 -0.2 -0.4
SONN 2021-08-24 NA 11.7 -0.2 -0.4

SONN Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at 44.67%.
  • Its 5 year net income to common stockholders growth rate is now at -58.38%.
  • The year over year net cashflow from operations growth rate now stands at -342.62%.
SONN's revenue has moved down $44,729,953 over the prior 70 months.

The table below shows SONN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 0.613425 -25.66291 -25.3077
2021-09-30 0.483626 -22.55224 -24.98396
2021-06-30 0 -22.15688 -66.89109
2021-03-31 0 -23.48151 -72.5546
2020-12-31 5.681238 -19.59896 -68.46528
2020-09-30 0 -15.61478 -65.60405

SONN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SONN has a Quality Grade of D, ranking ahead of 9.63% of graded US stocks.
  • SONN's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
  • QGEN, ALNY, and RDUS are the stocks whose asset turnover ratios are most correlated with SONN.

The table below shows SONN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 NA 6.121
2021-03-30 0.000 NA 8.723
2020-12-31 0.492 0.045 -7.708
2020-09-30 0.000 NA -2.244
2020-06-30 0.549 0.025 -1.292
2020-03-31 0.683 0.039 -0.581

SONN Price Target

For more insight on analysts targets of SONN, see our SONN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.50 Average Broker Recommendation 1.25 (Strong Buy)

SONN Stock Price Chart Interactive Chart >

Price chart for SONN

SONN Price/Volume Stats

Current price $0.27 52-week high $2.07
Prev. close $0.26 52-week low $0.24
Day low $0.26 Volume 581,600
Day high $0.27 Avg. volume 4,745,661
50-day MA $0.33 Dividend yield N/A
200-day MA $0.47 Market Cap 16.07M

Sonnet BioTherapeutics Holdings, Inc. (SONN) Company Bio


Sonnet BioTherapeutics Holdings, Inc. operates as a clinical stage biotechnology company. The Company develops fully human albumin binding technology that helps the development of innovative targeted biologic drugs with enhanced single-or bi-specific mechanisms. Sonnet BioTherapeutics Holdings serves customers in the United States.


SONN Latest News Stream


Event/Time News Detail
Loading, please wait...

SONN Latest Social Stream


Loading social stream, please wait...

View Full SONN Social Stream

Latest SONN News From Around the Web

Below are the latest news stories about Sonnet BioTherapeutics Holdings Inc that investors may wish to consider to help them evaluate SONN as an investment opportunity.

Analysts Offer Insights on Healthcare Companies: Sonnet BioTherapeutics Holdings (SONN), Armata Pharmaceuticals (ARMP) and Quotient (QTNT)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sonnet BioTherapeutics Holdings (SONN – Research Report), Armata Pharmaceuticals (ARMP – Research Report) and Quotient (QTNT – Research Report) with bullish sentiments. Sonnet BioTherapeutics Holdings (SONN) BTIG analyst Kaveri Pohlman maintained a Buy rating on Sonnet BioTherapeutics Holdings on February 8 and set a price target of $2.00. The company's shares closed last Wednesday at $0.31, close to its 52-week low of $0.28. According to TipRanks.

Catie Powers on TipRanks | February 10, 2022

H.C. Wainwright Thinks Sonnet BioTherapeutics Holdings’ Stock is Going to Recover

H.C. Wainwright analyst Michael King reiterated a Buy rating on Sonnet BioTherapeutics Holdings (SONN – Research Report) today and set a price target of $2.00. The company's shares closed last Wednesday at $0.31, close to its 52-week low of $0.28. According to TipRanks.com, King is a 4-star analyst with an average return of 12.4% and a 43.7% success rate. King covers the Healthcare sector, focusing on stocks such as Werewolf Therapeutics, Intellia Therapeutics, and Compass Therapeutics. Sonnet BioTherapeutics Holdings has an analyst consensus of Strong Buy, with a price target consensus of $3.17. See today’s best-performing stocks on TipRanks >> The company has a one-year high of $3.

Howard Kim on TipRanks | February 9, 2022

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting

PRINCETON, NJ / ACCESSWIRE / February 9, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that data from preclinical studies of the company's proprietary Fully Human Albumin Binding candidates, SON-1010, SON-1210, and SON-1410, will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, to be held April 8-13, in New Orleans,

Yahoo | February 9, 2022

Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update

* SON-1010 and SON-080 on track to initiate clinical studies during the second quarter of 2022 * Completed R&D manufacturing for SON-1210 non-GLP toxicity study in non-human primates, with study initiation planned for the first half of 2022 * Continue to advance preclinical development of FHAB pipelinePRINCETON, NJ / ACCESSWIRE / February 8, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic

Yahoo | February 8, 2022

BTIG Thinks Sonnet BioTherapeutics Holdings’ Stock is Going to Recover

In a report issued on December 17, Kaveri Pohlman from BTIG maintained a Buy rating on Sonnet BioTherapeutics Holdings (SONN – Research Report), with a price target of $5.00. The company's shares closed last Friday at $0.47, close to its 52-week low of $0.43. According to TipRanks.com, Pohlman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.2% and a 20.0% success rate. Pohlman covers the Healthcare sector, focusing on stocks such as Checkmate Pharmaceuticals, Mersana Therapeutics, and CytomX Therapeutics. Sonnet BioTherapeutics Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $3.50, which is a 605.

Christine Brown on TipRanks | December 20, 2021

Read More 'SONN' Stories Here

SONN Price Returns

1-mo -11.07%
3-mo -7.22%
6-mo -52.53%
1-year -82.58%
3-year -99.15%
5-year -99.64%
YTD -34.64%
2021 -81.48%
2020 -85.46%
2019 -54.26%
2018 -50.95%
2017 -37.38%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4427 seconds.